Latus Bio, founded in 2022, is innovating in the field of gene therapy with its focus on engineering scalable solutions for CNS disorders. The company is advancing novel therapeutics through the development of proprietary AAV capsids tailored for specific diseases such as CLN2 (Batten Disease) and Huntington’s Disease. These capsids are designed for exceptional potency and specificity, targeting the most pertinent brain regions and cell types.
Built on the pioneering research of Professor Beverly Davidson, Latus Bio is committed to improving patient care by reducing therapeutic load, enhancing safety, and expanding the accessibility of gene therapies. With a diverse team of experts, the company is strategically positioned to initiate clinical trials by late 2025, aiming to revolutionize healthcare for millions.
Investors should note Latus Bio's robust pipeline and visionary approach, which are supported by a commitment to patient-first innovations. The absence of a last investment round may indicate an early-stage opportunity for growth-focused capital engagement.
